The Medical Letter on Drugs and Therapeutics
Cobimetinib (Cotellic) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cobimetinib (Cotellic) for Metastatic Melanoma
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib (Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cobimetinib (Cotellic) for Metastatic Melanoma
Article code: 1491c
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.